← Leaderboards
Samuel Dagogo-Jack
Washington University
$9,603,669
Attributed
$10,593,616
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $987.1K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,593,616 · 12
By mechanism
R01$8,095,471 · 2
U01$2,173,600 · 1
T35$261,024 · 1
M01$63,521 · 8
Top collaborators
- Nawajes Mandal4 shared
Most similar at Washington University
Same institution · by research overlap
- Xianlin Han$13,463,600
- Megan Anne Cooper$7,117,802
- Usha R Acharya$4,232,744
- Fong-Fu Hsu$2,424,678
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusFollow-UpCohortDiabetes Prevention ProgramPrediabetes SyndromeNon-Insulin-Dependent Diabetes MellitusGlucoseParticipantRisk FactorsPhenotypePreventLifestyle InterventionBaseFunctional DisorderProgramsMetforminMicrovascular DysfunctionBlood VesselsMetabolicIncidenceReportingHigh RiskLipidsFunding
Grant awards (47)
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$438,755
R01 · FY2024 · DK · contact PI
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$505,964
R01 · FY2023 · DK · contact PI
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$504,642
R01 · FY2022 · DK · contact PI
9/22 Limited Competition for Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center$70,473
U01 · FY2022 · DK · contact PI
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$530,534
R01 · FY2021 · DK · contact PI
9/22 Limited Competition for Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center$225,708
U01 · FY2021 · DK · contact PI
Short Term Research Training for Medical Students$55,595
T35 · FY2021 · DK · contact PI
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$242,758
U01 · FY2020 · DK · contact PI
Short Term Research Training for Medical Students$53,649
T35 · FY2020 · DK · contact PI
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$280,654
U01 · FY2019 · DK · contact PI
Short Term Research Training for Medical Students$29,593
T35 · FY2019 · DK · contact PI
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$260,305
U01 · FY2018 · DK · contact PI
Short Term Research Training for Medical Students$61,612
T35 · FY2018 · DK · contact PI
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort$606,333
R01 · FY2017 · DK · contact PI
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$166,396
U01 · FY2017 · DK · contact PI
Short Term Research Training for Medical Students$60,575
T35 · FY2017 · DK · contact PI
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort$614,619
R01 · FY2016 · DK · contact PI
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$228,000
U01 · FY2016 · DK · contact PI
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$56,240
U01 · FY2016 · DK · contact PI
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$29,034
U01 · FY2016 · DK · contact PI
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort$611,234
R01 · FY2015 · DK · contact PI
DPPOS Follow-up$246,272
U01 · FY2015 · DK · contact PI
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort$619,338
R01 · FY2014 · DK · contact PI
Diabetes Prevention Program Outcomes Study-Phase 2$367,760
U01 · FY2014 · DK · contact PI
Pathobiology and Reversibility of Prediabetes in a Biracial Cohort$652,004
R01 · FY2013 · DK · contact PI
Pathobiology of Prediabetes in A Bi-Racial Cohort$697,996
R01 · FY2010 · DK · contact PI
Pathobiology of Prediabetes in A Bi-Racial Cohort$521,786
R01 · FY2009 · DK · contact PI
Pathobiology of Prediabetes in A Bi-Racial Cohort$117,931
R01 · FY2009 · DK · contact PI
Pathobiology of Prediabetes in A Bi-Racial Cohort$556,600
R01 · FY2008 · DK · contact PI
Pathobiology of Prediabetes in A Bi-Racial Cohort$528,900
R01 · FY2007 · DK · contact PI
Pathobiology of Prediabetes in A Bi-Racial Cohort$588,835
R01 · FY2006 · DK · contact PI
DCCT-EPIDEMIOLOGY OF DIABETES AND COMPLICATIONS (EDIC)$8,646
M01 · FY2006 · RR · contact PI
CDIP, DIABETES "TUNE UP"$4,900
M01 · FY2006 · RR · contact PI
CDIP, DIABETES "TUNE UP"$38,559
M01 · FY2005 · RR
DCCT-EPIDEMIOLOGY OF DIABETES AND CCOMPLICATIONS (EDIC)$4,975
M01 · FY2005 · RR
"ADDENDUM TO EDIC: GENETIC STUDIES OF DIABETES"$311
M01 · FY2005 · RR
DCCT-Epidemiology of Diabetes and Complications (EDIC)$4,768
M01 · FY2004 · RR
Addendum to EDIC: Genetic Studies of Diabetes$1,362
M01 · FY2004 · RR
METABOLIC SIGNIFICANCE OF OB PROTEIN (LEPTIN) IN HUMANS$0
M01 · FY2002 · RR
REGULATION OF LEPTIN IN HUMANS$0
M01 · FY2002 · RR
DIABETES PREVENTION PROGRAM PHASE 1,2,3 AND 4$0
M01 · FY2002 · RR
METABOLIC SIGNIFICANCE OF OB PROTEIN (LEPTIN) IN HUMANS$0
M01 · FY2001 · RR
REGULATION OF LEPTIN IN HUMANS$0
M01 · FY2001 · RR
DIABETES PREVENTION PROGRAM PHASE 1,2,3 AND 4$0
M01 · FY2001 · RR
METABOLIC SIGNIFICANCE OF OB PROTEIN (LEPTIN) IN HUMANS$0
M01 · FY2000 · RR
REGULATION OF LEPTIN IN HUMANS$0
M01 · FY2000 · RR
DIABETES PREVENTION PROGRAM PHASE 1,2,3 AND 4$0
M01 · FY2000 · RR